WEKO3
アイテム
{"_buckets": {"deposit": "5165227d-a802-4a67-95a1-a0143b726fef"}, "_deposit": {"created_by": 15, "id": "5520", "owners": [15], "pid": {"revision_id": 0, "type": "depid", "value": "5520"}, "status": "published"}, "_oai": {"id": "oai:air.repo.nii.ac.jp:00005520", "sets": ["940", "922"]}, "author_link": ["15548", "15549", "15550", "15551", "15552", "15553", "15554", "8893"], "control_number": "5520", "item_10001_biblio_info_7": {"attribute_name": "書誌情報", "attribute_value_mlt": [{"bibliographicIssueDates": {"bibliographicIssueDate": "2021", "bibliographicIssueDateType": "Issued"}, "bibliographicIssueNumber": "1054", "bibliographicVolumeNumber": "10", "bibliographic_titles": [{"bibliographic_title": "Biology"}]}]}, "item_10001_description_5": {"attribute_name": "内容記述(抄録)", "attribute_value_mlt": [{"subitem_description": "We evaluated the area under the plasma concentration–time curve (AUC) of afatinib required to avoid the onset of grade 2 or higher diarrhea. The C0 and AUC0–24 of afatinib were significant higher in patients with grade 2 diarrhea than in those with grade 0–1 diarrhea. The areas under the receiver operator curves were 0.795 with the highest sensitivity (89%) and specificity (74%) at an AUC0–24 threshold of 823.5 ng h/mL, and 0.754 with the highest sensitivity (89%) and specificity (74%) at a C0 threshold of 28.5 ng/mL. In Kaplan–Meier analysis based on these cut-off AUC0–24 and C0 values, the median time to the incidence of grade 2 diarrhea was 16 days. The predicted AUC0–24 of afatinib from the single point of C6 showed the highest correlation with the measured AUC0–24 (r2 = 0.840); however, a significant correlation between the AUC0–24 and C0 was also observed (r2 = 0.761). C0 could be used as a marker of therapeutic drug monitoring because afatinib C0 was related to AUC0–24. Therefore, afatinib C0 should be monitored on day 8 after beginning therapy, and the daily dose of afatinib should be adjusted as an index with a cut-off value of 28.5 ng/mL.", "subitem_description_type": "Other"}]}, "item_10001_publisher_8": {"attribute_name": "出版者", "attribute_value_mlt": [{"subitem_publisher": "MDPI"}]}, "item_10001_relation_14": {"attribute_name": "DOI", "attribute_value_mlt": [{"subitem_relation_type": "isIdenticalTo", "subitem_relation_type_id": {"subitem_relation_type_id_text": "10.3390/biology10101054", "subitem_relation_type_select": "DOI"}}]}, "item_10001_relation_25": {"attribute_name": "関連リンク", "attribute_value_mlt": [{"subitem_relation_type_id": {"subitem_relation_type_id_text": "https://doi.org/10.3390/biology10101054", "subitem_relation_type_select": "DOI"}}]}, "item_10001_rights_15": {"attribute_name": "著作権等", "attribute_value_mlt": [{"subitem_rights": "Copyright: © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https:// creativecommons.org/licenses/by/ 4.0/)."}]}, "item_10001_source_id_9": {"attribute_name": "ISSN", "attribute_value_mlt": [{"subitem_source_identifier": "2079-7737", "subitem_source_identifier_type": "ISSN"}]}, "item_10001_version_type_20": {"attribute_name": "著者版フラグ", "attribute_value_mlt": [{"subitem_version_resource": "http://purl.org/coar/version/c_970fb48d4fbd8a85", "subitem_version_type": "VoR"}]}, "item_creator": {"attribute_name": "著者", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "Yokota, Hayato"}], "nameIdentifiers": [{"nameIdentifier": "15548", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Sato, Kazuhiro"}], "nameIdentifiers": [{"nameIdentifier": "15549", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Sakamoto, Sho"}], "nameIdentifiers": [{"nameIdentifier": "15550", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Okuda, Yuji"}], "nameIdentifiers": [{"nameIdentifier": "15551", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Asano, Mariko"}], "nameIdentifiers": [{"nameIdentifier": "15552", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Takeda, Masahide"}], "nameIdentifiers": [{"nameIdentifier": "15553", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Nakayama, Katsutoshi"}], "nameIdentifiers": [{"nameIdentifier": "15554", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Miura, Masatomo"}], "nameIdentifiers": [{"nameIdentifier": "8893", "nameIdentifierScheme": "WEKO"}]}]}, "item_files": {"attribute_name": "ファイル情報", "attribute_type": "file", "attribute_value_mlt": [{"accessrole": "open_date", "date": [{"dateType": "Available", "dateValue": "2021-11-25"}], "displaytype": "detail", "download_preview_message": "", "file_order": 0, "filename": "byoA_2021_1.pdf", "filesize": [{"value": "771.5 kB"}], "format": "application/pdf", "future_date_message": "", "is_thumbnail": false, "licensefree": "CC BY 4.0", "licensetype": "license_free", "mimetype": "application/pdf", "size": 771500.0, "url": {"label": "byoA_2021_1", "url": "https://air.repo.nii.ac.jp/record/5520/files/byoA_2021_1.pdf"}, "version_id": "dd7b0459-0c74-4b74-8b9b-ba7787321056"}]}, "item_keyword": {"attribute_name": "キーワード", "attribute_value_mlt": [{"subitem_subject": "afatinib", "subitem_subject_scheme": "Other"}, {"subitem_subject": "diarrhea", "subitem_subject_scheme": "Other"}, {"subitem_subject": "limited sampling strategy", "subitem_subject_scheme": "Other"}, {"subitem_subject": "plasma concentration", "subitem_subject_scheme": "Other"}, {"subitem_subject": "therapeutic drug monitoring", "subitem_subject_scheme": "Other"}]}, "item_language": {"attribute_name": "言語", "attribute_value_mlt": [{"subitem_language": "eng"}]}, "item_resource_type": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"resourcetype": "journal article", "resourceuri": "http://purl.org/coar/resource_type/c_6501"}]}, "item_title": "Relationship between Plasma Concentrations of Afatinib and the Onset of Diarrhea in Patients with Non-Small Cell Lung Cancer", "item_titles": {"attribute_name": "タイトル", "attribute_value_mlt": [{"subitem_title": "Relationship between Plasma Concentrations of Afatinib and the Onset of Diarrhea in Patients with Non-Small Cell Lung Cancer", "subitem_title_language": "en"}]}, "item_type_id": "10001", "owner": "15", "path": ["940", "922"], "permalink_uri": "http://hdl.handle.net/10295/00005837", "pubdate": {"attribute_name": "PubDate", "attribute_value": "2021-11-25"}, "publish_date": "2021-11-25", "publish_status": "0", "recid": "5520", "relation": {}, "relation_version_is_last": true, "title": ["Relationship between Plasma Concentrations of Afatinib and the Onset of Diarrhea in Patients with Non-Small Cell Lung Cancer"], "weko_shared_id": -1}
Relationship between Plasma Concentrations of Afatinib and the Onset of Diarrhea in Patients with Non-Small Cell Lung Cancer
http://hdl.handle.net/10295/00005837
http://hdl.handle.net/10295/00005837de235fe9-514e-4717-b062-3cc20e15ae4d
名前 / ファイル | ライセンス | アクション |
---|---|---|
byoA_2021_1 (771.5 kB)
|
CC BY 4.0
|
Item type | 学術雑誌論文 / Journal Article(1) | |||||
---|---|---|---|---|---|---|
公開日 | 2021-11-25 | |||||
タイトル | ||||||
言語 | en | |||||
タイトル | Relationship between Plasma Concentrations of Afatinib and the Onset of Diarrhea in Patients with Non-Small Cell Lung Cancer | |||||
言語 | ||||||
言語 | eng | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | afatinib | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | diarrhea | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | limited sampling strategy | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | plasma concentration | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | therapeutic drug monitoring | |||||
資源タイプ | ||||||
資源タイプ識別子 | http://purl.org/coar/resource_type/c_6501 | |||||
資源タイプ | journal article | |||||
著者 |
Yokota, Hayato
× Yokota, Hayato× Sato, Kazuhiro× Sakamoto, Sho× Okuda, Yuji× Asano, Mariko× Takeda, Masahide× Nakayama, Katsutoshi× Miura, Masatomo |
|||||
内容記述(抄録) | ||||||
内容記述タイプ | Other | |||||
内容記述 | We evaluated the area under the plasma concentration–time curve (AUC) of afatinib required to avoid the onset of grade 2 or higher diarrhea. The C0 and AUC0–24 of afatinib were significant higher in patients with grade 2 diarrhea than in those with grade 0–1 diarrhea. The areas under the receiver operator curves were 0.795 with the highest sensitivity (89%) and specificity (74%) at an AUC0–24 threshold of 823.5 ng h/mL, and 0.754 with the highest sensitivity (89%) and specificity (74%) at a C0 threshold of 28.5 ng/mL. In Kaplan–Meier analysis based on these cut-off AUC0–24 and C0 values, the median time to the incidence of grade 2 diarrhea was 16 days. The predicted AUC0–24 of afatinib from the single point of C6 showed the highest correlation with the measured AUC0–24 (r2 = 0.840); however, a significant correlation between the AUC0–24 and C0 was also observed (r2 = 0.761). C0 could be used as a marker of therapeutic drug monitoring because afatinib C0 was related to AUC0–24. Therefore, afatinib C0 should be monitored on day 8 after beginning therapy, and the daily dose of afatinib should be adjusted as an index with a cut-off value of 28.5 ng/mL. | |||||
著者版フラグ | ||||||
出版タイプ | VoR | |||||
出版タイプResource | http://purl.org/coar/version/c_970fb48d4fbd8a85 | |||||
DOI | ||||||
関連タイプ | isIdenticalTo | |||||
識別子タイプ | DOI | |||||
関連識別子 | 10.3390/biology10101054 | |||||
書誌情報 |
Biology 巻 10, 号 1054, 発行日 2021 |
|||||
ISSN | ||||||
収録物識別子タイプ | ISSN | |||||
収録物識別子 | 2079-7737 | |||||
出版者 | ||||||
出版者 | MDPI | |||||
関連リンク | ||||||
識別子タイプ | DOI | |||||
関連識別子 | https://doi.org/10.3390/biology10101054 | |||||
著作権等 | ||||||
権利情報 | Copyright: © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https:// creativecommons.org/licenses/by/ 4.0/). |